I-STAR Technology may identify effective therapies against Ebola
The company’s technology is a powerful human memory B-cell interrogation platform. It can quickly screen the antibodies within Ebola survivors. This enables researchers to discover which people have exceptional biologic activity, which may further potential therapeutic antibodies currently being developed.
“Our platform offers a comprehensive and rapid means to identify fully human immunotherapies for even the most difficult-to-treat infectious diseases, such as Ebola,” Chief Executive Officer of Theraclone Clifford J. Stocks said. “This Ebola project expands upon the multitude of ongoing partnerships we have with our I-STAR technology, demonstrating its broad applicability across diverse areas, including oncology, HIV and other infectious diseases. We are pleased with the confidence Wellcome Trust has shown in our platform, and we are excited to commence the project with our consortium of collaborators assembled with the kind assistance of BIO Ventures for Global Health.”
To continue developing efforts, Theraclone will soon receive Series C financing amounting to $4.4 million. Part of these investments include funds from the Wellcome Trust as well as preexisting investors of Theraclone. BIO Ventures for Global Health has been key to assisting with the technology development and management.
“Ebola, like many infectious diseases, is now a global threat,” Jennifer Dent, president of BVGH, said. “New collaborative approaches with researchers and clinicians from impacted countries, disease experts and antibody therapeutic scientists from biotechnology companies are desperately needed to develop new and effective products. BVGH is proud to bring these partners together and to work with Theraclone to help bring new therapies to all people worldwide.”